Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
ACR Open Rheumatol ; 2024 May 11.
Article in English | MEDLINE | ID: mdl-38733262

ABSTRACT

OBJECTIVE: Positive antineutrophil cytoplasmic antibodies (ANCAs) may occur in the setting of interstitial lung disease (ILD), with or without ANCA-associated vasculitis (AAV). We aim to compare the characteristics and clinical course of patients with ILD and positive ANCA (ANCA-ILD) to those with negative ANCA. METHODS: We performed a single-center retrospective cohort study from 2018 to 2021. All patients with ILD and ANCA testing were included. Patient characteristics (symptoms, dyspnea scale, and systemic AAV), test results (pulmonary high-resolution computed tomography and pulmonary function tests), and adverse events were collected from electronic medical records. Descriptive statistics and the Fisher exact test were used to compare the outcomes of patients with ANCA-ILD to those with ILD and negative ANCA. RESULTS: A total of 265 patients with ILD were included. The mean follow-up duration was 69.3 months, 26 patients (9.8%) were ANCA positive, and 69.2% of those with ANCA-ILD had another autoantibody. AAV occurred in 17 patients (65.4%) with ANCA-ILD. In 29.4% of patients, AAV developed following ILD diagnosis. Usual interstitial pneumonia was the most common radiologic pattern in patients with ANCA-ILD. There was no association between ANCA status and the evolution of dyspnea, diffusing capacity of the lungs for carbon monoxide, and lung imaging. Forced vital capacity improved over time in 42% of patients with ANCA-ILD and in 17% of patients with negative ANCA (P = 0.006). Hospitalization occurred in 46.2% of patients with ANCA-ILD and in 21.8% of patients with negative ANCA (P = 0.006). Both groups had similar mortality rates. CONCLUSION: Routine ANCA testing should be considered in patients with ILD. Patients with ANCA-ILD are at risk for AAV. More research is required to better understand and manage patients with ANCA-ILD.

2.
CJC Open ; 2(6): 619-624, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33305222

ABSTRACT

BACKGROUND: Antithrombotic management following acute coronary syndromes (ACSs) has evolved significantly. However, given lingering uncertainty as to when an ACS may be considered stable, there is the possibility of practice divergence beyond the first year. METHODS: An online adaptive survey describing patients with varying cardiac and extracardiac ischemic risk was developed in order to asses self-reported physician practice intentions pertaining to the antithrombotic management of ACS patients who lack a formal indication for therapeutic anticoagulation. Provincial "champions" (Prince Edward Island not represented) were identified to ensure dissemination of the survey within their jurisdictions via 3 coordinated e-mailings; the survey was made available in French and English from November 2018 through January 2019. RESULTS: A total of 135 practitioners responded to the survey (response rate 15%). Surveys were fully completed in all cases. Nearly all respondents (97%) were cardiologists; 76% worked at an academic center, and 54% had been in practice ≥ 10 years. Most respondents (81%-90%, depending on the scenario) preferred ticagrelor-based dual antiplatelet therapy as the initial ACS treatment. However, beyond 12 months, management decisions differed significantly according to the balance of cardiac and extracardiac risk. CONCLUSIONS: This study provides a first look at how the introduction of rivaroxaban 2.5 mg might be integrated into the clinical management of ACS patients beyond the first year in Canada. Whether to pursue dual antiplatelet therapy or transition early to low-dose rivaroxaban plus acetylsalicylic acid will likely be driven by patient clinical characteristics and perceived cardiac vs extra-cardiac ischemic risk.


CONTEXTE: La prise en charge antithrombotique des patients ayant subi un syndrome coronarien aigu (SCA) a sensiblement évolué au fil du temps. Toutefois, compte tenu de l'incertitude qui persiste quant aux critères définissant un SCA stable, il est possible que les pratiques divergent après la première année. MÉTHODOLOGIE: Nous avons mis au point un questionnaire adaptatif en ligne décrivant les cas de patients présentant divers degrés de risque d'ischémie cardiaque ou extracardiaque, afin d'évaluer les objectifs autodéclarés des médecins quant à la prise en charge antithrombotique des patients ayant subi un SCA chez qui une anticoagulothérapie n'est pas formellement indiquée. Des « champions ¼ provinciaux (l'Île-du-Prince-Édouard n'étant pas représentée) ont été désignés pour assurer la diffusion du questionnaire dans leur province respective en trois envois par courriel coordonnés; le questionnaire était offert en français et en anglais, et l'enquête s'est déroulée de novembre 2018 à janvier 2019. RÉSULTATS: Au total, 135 praticiens ont répondu au sondage (taux de réponse : 15 %). Tous les participants ont répondu à toutes les questions. Presque tous les participants (97 %) étaient cardiologues; 76 % des participants travaillaient dans un centre universitaire, et 54 % exerçaient depuis 10 ans ou plus. La plupart des participants (de 81 à 90 %, selon le scénario) préféraient une bithérapie antiplaquettaire à base de ticagrélor comme premier traitement après un SCA. Toutefois, les décisions quant au traitement au-delà des 12 premiers mois suivant le SCA variaient considérablement selon le risque cardiaque et extracardiaque résiduel évalué. CONCLUSIONS: L'étude constitue une première évaluation de la façon dont le rivaroxaban à 2,5 mg pourrait être intégré à la stratégie canadienne de prise en charge des patients au-delà de la première année suivant le SCA. Le choix de poursuivre la bithérapie antiplaquettaire ou de faire promptement la transition vers un traitement associant rivaroxaban à faible dose et acide acétylsalicylique dépendra vraisemblablement des caractéristiques cliniques du patient et du risque d'ischémie cardiaque et extracardiaque perçu.

3.
PLoS One ; 15(6): e0233272, 2020.
Article in English | MEDLINE | ID: mdl-32542011

ABSTRACT

BACKGROUND: There is limited evidence of non-ST elevation acute coronary syndrome (NSTE-ACS) in patients aged 80 or older in Vietnam. AIM: To describe the clinical characteristics of patients aged≥80 with NSTE-ACS in Vietnam, and to examine the effect of percutaneous coronary intervention (PCI) on adverse outcomes. METHODS: Consecutive patients aged ≥80 with a diagnosis of NSTE-ACS admitted to two tertiary hospitals in Vietnam from 12/2018 to 06/2019 were recruited. The major outcomes were: (1) the composite of all-cause mortality, recurrent myocardial infarction and stroke, (2) re-admission rate during 3 months. Cox proportional-hazards regressions were conducted to examine the impact of PCI on the study outcomes, with results presented as hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: There were 120 participants, mean age 84.8 ± 3.8, 50% were female. Angiography and PCI were performed in 42 participants (35.0%). Most of the participants had multimorbidity and multiple coronary vessel disease. Compared to participants who did not receive PCI, participants who received PCI had significantly lower rates of adverse events during hospitalisation and during 3 months of follow up. Cox proportional hazards models adjusted to age and GRACE score show that PCI was significantly associated with reduced the composite outcome of all-cause mortality, recurrent myocardial infarction and stroke during 3 months follow-up (adjusted HR 0.32, 95%CI 0.12-0.86). PCI was also associated with reduced re-admission. CONCLUSIONS: The rate of PCI was low in the very elderly patients with NSTE-ACS in this study, although PCI was significantly associated with reduced adverse outcomes.


Subject(s)
Acute Coronary Syndrome/epidemiology , Non-ST Elevated Myocardial Infarction/epidemiology , Percutaneous Coronary Intervention/adverse effects , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/mortality , Aged, 80 and over , Coronary Angiography , Coronary Artery Disease/complications , Female , Humans , Kaplan-Meier Estimate , Male , Myocardial Infarction/mortality , Non-ST Elevated Myocardial Infarction/diagnosis , Non-ST Elevated Myocardial Infarction/mortality , Percutaneous Coronary Intervention/methods , Proportional Hazards Models , Stroke/complications , Treatment Outcome , Vietnam/epidemiology
4.
Australas J Ageing ; 39(3): e315-e321, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32270595

ABSTRACT

OBJECTIVE: To investigate the prevalence of sarcopenia, its associated factors and its impact on readmission in older hospitalised patients with cardiovascular diseases (CVD) in Vietnam. METHODS: Patients aged ≥60 with CVD were recruited from 12/2018 to 6/2019 at a tertiary hospital in Vietnam. Sarcopenia was defined by the criteria proposed by the Asian Working Group for Sarcopenia (AWGS). RESULTS: There were 251 participants, with a mean age of 73.7 ± 8.8, 39.4% were female, and 34.3% had sarcopenia. On multivariable logistic regression, heart failure, chronic kidney disease and being currently unmarried were significantly associated with sarcopenia. The incidence of 5-month readmission was 35.7% (50.0% in sarcopenic participants and 27.9% in non-sarcopenic participants, P = .001). Sarcopenia independently increased the risk of readmission (adjusted OR 2.19, 95% CI 1.08-4.42). CONCLUSION: Sarcopenia was present in one-third of older hospitalised patients with CVD and increased their risk of readmission. This finding suggests the need to raise awareness of sarcopenia among clinicians and older patients in Vietnam.


Subject(s)
Cardiovascular Diseases , Sarcopenia , Aged , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/therapy , Cross-Sectional Studies , Female , Humans , Incidence , Prevalence , Sarcopenia/diagnosis , Sarcopenia/epidemiology , Sarcopenia/therapy , Vietnam/epidemiology
5.
Clin Interv Aging ; 14: 2213-2222, 2019.
Article in English | MEDLINE | ID: mdl-31908432

ABSTRACT

BACKGROUND: There has been limited evidence about frailty in older patients with acute coronary syndrome (ACS) in Vietnam. AIM: (1) To investigate the prevalence of frailty in older patients hospitalised with ACS and its associated factors; (2) To investigate the impact of frailty on percutaneous coronary intervention (PCI) and adverse outcomes in this population. METHODS: Patients aged ≥60 with ACS admitted to two teaching hospitals in Vietnam were recruited from 9/2017 to 4/2018. Frailty was defined by the Reported Edmonton Frail Scale. Multivariate logistic regression was applied to investigate the associated factors of frailty and the impact of frailty on PCI and adverse outcomes. RESULTS: There were 324 participants, mean age 73.5±8.3, 39.2% female. The prevalence of frailty was 48.1%. Advanced age, female gender, history of hypertension, heart failure, stroke and chronic kidney disease were significantly associated with a frailty status. Overall, 50.3% of the participants received PCI (58.3% in the non-frail vs 41.7% in the frail, p=0.003). However, frailty did not have an independent impact on PCI (adjusted OR 0.66, 95% CI 0.41-1.08). Frailty was significantly associated with increased risk of having arrhythmia during hospitalisation (adjusted OR 2.24, 95% CI 1.32-3.80), hospital-acquired pneumonia (adjusted OR 2.27, 95% CI 1.24-4.17), in-hospital mortality (adjusted OR 3.02, 95% CI 1.35-6.75), 30-day mortality (adjusted OR 3.28, 95% CI 1.59-6.76), and 30-day readmission (adjusted OR 2.53, 95% CI 1.38-4.63). CONCLUSION: In this study, frailty was present in nearly half of older patients with ACS and was associated with increased adverse outcomes. These findings suggest that frailty screening should be performed in older patients with ACS in Vietnam.


Subject(s)
Acute Coronary Syndrome/epidemiology , Frail Elderly/statistics & numerical data , Frailty/epidemiology , Percutaneous Coronary Intervention/methods , Postoperative Complications/etiology , Acute Coronary Syndrome/surgery , Aged , Comorbidity/trends , Female , Hospital Mortality/trends , Hospitalization/statistics & numerical data , Humans , Male , Postoperative Complications/epidemiology , Prevalence , Vietnam/epidemiology
6.
Epilepsy Res ; 148: 63-68, 2018 12.
Article in English | MEDLINE | ID: mdl-30390542

ABSTRACT

BACKGROUND: Epilepsy surgery is likely underutilised. Our goal was to study the utilisation of epilepsy surgery in the general population, using Canada as a model of a high-income country with universal medical coverage. METHODS: We systematically identified all epilepsy surgery centres in Canada that were active in 2015. A standardised questionnaire was completed by every centre. Descriptive statistics are reported. Comparisons were made to a 2003 survey of paediatric epilepsy surgery. RESULTS: Twelve adult and 11 paediatric epilepsy surgery centres were identified, performing a total of 456 and 206 surgical procedures, respectively, in 2015. Adult centres were in only six of 10 provinces; paediatric centres were in seven. Two thirds of adult centres and one third of paediatric centres were high-volume centres. Per capita volume per province varied between 7.0 and 20.5 therapeutic surgeries per million adult residents, and between 7.8 and 48.4 per million paediatric residents. Temporal lobe resections accounted for 59.8% and 33.5% of all adult and paediatric treatments, respectively. Eleven adult and nine paediatric centres possessed facilities to carry out intracranial investigations but only six and two, respectively, performed at least six intracranial implantations in 2015. There was a modest increase in the per capita number of paediatric surgeries between 2003 and 2015. CONCLUSIONS: There is dramatic inter-centre and interprovincial variability in the epilepsy services available and the type of surgical interventions performed with significant gaps identified in some regions. Our findings are pivotal for the future optimisation of care offered to this vulnerable patient population.


Subject(s)
Epilepsy/epidemiology , Epilepsy/surgery , Healthcare Disparities , Patient Acceptance of Health Care , Adult , Canada/epidemiology , Child , Humans
7.
Pharm. pract. (Granada, Internet) ; 9(1): 1-10, ene.-mar. 2011. tab, ilus
Article in English | IBECS | ID: ibc-86120

ABSTRACT

The short-comings of current anticoagulants have led to the development of newer, albeit more expensive, oral alternatives. Objective: To explore the potential impact the new anticoagulants dabigatran and rivaroxaban in the local hospital setting, in terms of utilisation and subsequent costing. Method: A preliminary costing analysis was performed based on a prospective 2-week clinical audit (29th June - 13th July 2009). Data regarding current anticoagulation management were extracted from the medical files of patients admitted to Ryde Hospital. To model potential costing implications of using the newer agents, the reported incidence of VTE/stroke and bleeding events were obtained from key clinical trials. Results: Data were collected for 67 patients treated with either warfarin (n=46) or enoxaparin (n=21) for prophylaxis of VTE/stroke. At least two-thirds of all patients were deemed suitable candidates for the use of newer oral anticoagulants (by current therapy: warfarin: 65.2% (AF), 34.8% (VTE); enoxaparin: 100%, (VTE)). The use of dabigatran in VTE/stroke prevention was found to be more costeffective than warfarin and enoxaparin due to significantly lower costs of therapeutic monitoring and reduced administration costs. Rivaroxaban was more cost-effective than warfarin and enoxaparin for VTE/stroke prevention when supplier-rebates (33%) were factored into costing. Conclusion: This study highlights the potential costeffectiveness of newer anticoagulants, dabigatran and rivaroxaban, compared to warfarin and enoxaparin. These agents may offer economic advantages, as well as clinical benefits, in the hospital-based management of anticoagulated patients (AU)


Los defectos de los actuales anticoagulantes han llevado al desarrollo de nuevas y, a la vez más caras, alternativas orales. Objetivo: Explorar el impacto potencial de los nuevos anticoagulantes dabigatran y rivaroxaban en el ambiente hospitalario local, en términos de utilización y subsiguiente coste. Método: Se realizó un análisis de costes preliminar basado en una auditoria clínica prospectiva de 2 semanas (29 junio - 13 julio de 2009). Se extrajeron los datos relativos al manejo actual de la anticoagulación de las historias clínicas de los pacientes ingresados en el Hospital Ryde. Para modelizar implicaciones potenciales del uso de los nuevos agentes en el coste, se obtuvieron de los ensayos clínicos clave los datos de incidencia comunicada de tromboembolismo venososo/infarto y hemorragias. Resultados: Se recogieron datos de 67 pacientes tratados o con warfarina (n=46) o enoxaparina (n=21) para la profilaxis de TEV/infarto. Al menos dos tercios de todos los pacientes fueron considerados candidatos para el uso de los nuevos anticoagulantes orales (por tratamiento actual: warfarina: 65.2% (fibrilación), 34.8% (TEV); enoxaparina: 100%, (TEV)). El uso de dabigatran para la prevención de TEV/infarto se vio más costeefectivo que la warfarina y la enoxaparina, debido a los significativamente menores costes de la monitorización y menores costes de administración. El rivaroxaban fue más coste-efectivo que la warfarina y la enoxiparina para prevención de TEV/infarto cuando se tuvieron en cuenta los descuentos del 33 del proveedor. Conclusión: Este estudio ensalza la posible costeefectividad de los nuevos anticoagulantes dabigatran y rivaroxaban, comparados con warfarina y enoxiparina. Estos agentes pueden ofrecer ventajas económicas, así como beneficios clínicos, en el manejo hospitalario de pacientes anticoagulados (AU)


Subject(s)
Humans , Male , Female , Anticoagulants/analysis , Cost Allocation/organization & administration , Cost Allocation , Costs and Cost Analysis/methods , Costs and Cost Analysis/trends , Clinical Audit/economics , Clinical Audit/statistics & numerical data , Pulmonary Embolism/economics , Thromboembolism/economics , Thromboembolism/epidemiology , Anticoagulants/therapeutic use , Pulmonary Embolism/drug therapy , Commission on Professional and Hospital Activities/economics , Financial Audit , Medical Audit/methods , Medical Audit/statistics & numerical data , Warfarin/economics , Enoxaparin/economics
8.
Pharm Pract (Granada) ; 9(1): 1-10, 2011 Jan.
Article in English | MEDLINE | ID: mdl-25132883

ABSTRACT

UNLABELLED: The short-comings of current anticoagulants have led to the development of newer, albeit more expensive, oral alternatives. OBJECTIVE: To explore the potential impact the new anticoagulants dabigatran and rivaroxaban in the local hospital setting, in terms of utilisation and subsequent costing. METHOD: A preliminary costing analysis was performed based on a prospective 2-week clinical audit (29th June - 13th July 2009). Data regarding current anticoagulation management were extracted from the medical files of patients admitted to Ryde Hospital. To model potential costing implications of using the newer agents, the reported incidence of VTE/stroke and bleeding events were obtained from key clinical trials. RESULTS: Data were collected for 67 patients treated with either warfarin (n=46) or enoxaparin (n=21) for prophylaxis of VTE/stroke. At least two-thirds of all patients were deemed suitable candidates for the use of newer oral anticoagulants (by current therapy: warfarin: 65.2% (AF), 34.8% (VTE); enoxaparin: 100%, (VTE)). The use of dabigatran in VTE/stroke prevention was found to be more cost- effective than warfarin and enoxaparin due to significantly lower costs of therapeutic monitoring and reduced administration costs. Rivaroxaban was more cost-effective than warfarin and enoxaparin for VTE/stroke prevention when supplier-rebates (33%) were factored into costing. CONCLUSION: This study highlights the potential cost- effectiveness of newer anticoagulants, dabigatran and rivaroxaban, compared to warfarin and enoxaparin. These agents may offer economic advantages, as well as clinical benefits, in the hospital-based management of anticoagulated patients.

SELECTION OF CITATIONS
SEARCH DETAIL
...